PROJECT RESULTS

Results of research

In this section you can learn about the results of the projects funded by the Foundation, selecting them by scientific area and year.

Filter by

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models

FFC#4/2023

Pseudopaline–aztreonam conjugates exhibited enhanced antimicrobial activity against Pseudomonas aeruginosa compared to aztreonam alone

FFC#10/2023

Several drugs already approved for human use inhibit the growth of P. aeruginosa, its virulence, or its ability to form biofilms in vitro

FFC#11/2023

A phage-derived endolysin is effective in vitro in eliminating Mycobacterium abscessus

AREA 4 Lung inflammation

FFC#2/2022

Characterization of CFTR modulators mechanism of action via Photo-Affinity Labeling (PAL) approach

FFC#3/2022

The PI3Kγ peptide has a stabilizing effect on CFTR and enhances the effect of Kaftrio

FFC#4/2022

Esc peptides stabilize the opening of the CFTR channel and exhibit antibacterial activity against P. aeruginosa and S. aureus both in vitro and in vivo models

FFC#5/2022

The chemical structure of inhibitors of the salicylate synthase enzyme from Mycobacterium abscessus has been identified to reduce the bacterium's virulence

FFC#9/2022

Effect of inflammatory stimuli on airway epithelium ion transport in cystic fibrosis

FFC#10/2022

GY971a has demonstrated anti-inflammatory activity without showing toxicity either in vitro on cells or in vivo models

FFC#11/2022

Resolvin D3 and Resolvin E1 are able to reduce platelet hyperactivation in vitro, modulating the inflammatory response in the airways

FFC#12/2022

The DEV phage has anti-inflammatory effects and, in zebrafish, acts on macrophages by modulating their activity

FFC#14/2022

The DNase1 and DNase1L2 enzymes, modified through PEGylation, more effectively reduce mucus viscosity compared to the unmodified enzyme

FFC#13/2022

The combined therapy of liposomes and amikacin is able to combat Mycobacterium abscessus infection and reduce inflammation in both in vitro and in vivo models

FFC#6/2022

Search for drug combinations killing Mycobacterium abscessus in cystic fibrosis

FFC#1/2021

Multiomics exploration of the CF primary bronchial epithelium lipidome and its role on CFTR rescue

FFC#2/2021

Harnessing CRISPR-Cas technology to revert F508del and 2789+5G>A CFTR defects

FFC#3/2021

Toward the development of tailored therapies for insensitive CF gating mutations

FFC#4/2021

Oxidative stress and autophagy in Cystic Fibrosis: Novel biochemical characterizations and drug discovery approaches

FFC#5/2021

In vitro evaluation of novel sequence-specific RNA editing tools to rescue nonsense mutant CFTR transcript

FFC#6/2021

Enhancing the prediction of clinical responses to CFTR modulators by in vitro assays using patient-derived tissues under conditions mimicking native status of CF airways

FFC#7/2021

Monocyte integrin activation as a cystic fibrosis drug evaluation test: validation phase

FFC#8/2021

Theratyping of cystic fibrosis

FFC#9/2021

Lead optimization of MKT-077 analogues as HSP70 allosteric inhibitors combined with F508del CFTR correctors: a multi-drug approach to contrast cystic fibrosis

FFC#10/2021

Theratyping orphan mutations in Italian cystic fibrosis patients: meeting unmet needs

FFC#11/2021

Alternative targets for the treatment of cystic fibrosis basic defect

FFC#12/2021

Pharmacological inhibition of colistin resistance in Gram-negative cystic fibrosis pathogens

FFC#13/2021

Probiotics: an emerging strategy to fight bacterial pulmonary infections in CF

FFC#14/2021

Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa

FFC#15/2021

Tackling phage resistance to increase the robustness of phage therapy for curing Pseudomonas aeruginosa infections in patients with cystic fibrosis (PhaCyf)

FFC#16/2021

Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease

FFC#17/2021

New drug combinations against non-tuberculous mycobacteria infections in cystic fibrosis

FFC#18/2021

New weapons against Mycobacterium abscessus and other nontuberculous Mycobacteria

FFC#19/2021

Exploring the dual targeting of host and microbial sphingosine-1-phosphate lyase as antimicrobial strategy in cystic fibrosis

FFC#20/2021

Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic

FFC#21/2021

Mental Health in cystic fibrosis patients: the prognostic role of temperament, personality and attachment styles

FFC#1/2020

Peptide-nucleic acids as potential CFTR amplifier molecules for cystic fibrosis treatment

FFC#2/2020

Lipid-based therapeutic strategies to optimize the effectiveness of innovative drugs to rescue F508del-CFTR

FFC#3/2020

Small nitrogen heterocycles as correctors of the mutant CFTR protein in cystic fibrosis

FFC#4/2020

Characterization of CFTR modulators mechanism of action via Photo-Affinity Labeling (PAL) approach

FFC#5/2020

Intestinal organoids for assessment and pharmacological correction of abnormalities in fluid transport and anion currents in patients affected by pancreatitis

FFC#6/2020

Validation of the distribution and activity of new optimized leads in mouse model and other CF model systems

FFC#7/2020

Functional role of post-translational modifications in F508del-CFTR correction

FFC#8/2020

Establishment of Conditionally Reprogrammed Airway Epithelial Stem Cell cultures from nasal epithelia of Cystic Fibrosis patients: exploring response to CFTR-modulating drugs for correlation with genetic profile (theratyping) and restoring CFTR function through gene editing approaches

FFC#9/2020

Theratyping of rare CFTR genotypes for treatment with CFTR modulators

FFC#10/2020

Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa

FFC#11/2020

Disrupting Pseudomonas aeruginosa Quorum Sensing signalling in Cystic Fibrosis patients as a new frontier for antibacterial therapy

FFC#12/2020

New drug combinations against non-tuberculous mycobacteria infections in cystic fibrosis

FFC#13/2020

Can old and new sweet glycomimetics act as antibacterial and antibiofilm agents in the treatment of CF lung disease infections?

FFC#14/2020

New weapons against Mycobacterium abscessus and other nontuberculous mycobacteria